Positive correlation between serum omentin and thrombospondin-1 in gestational diabetes despite lack of correlation with insulin resistance indices;Dodatnia korelacja pomiędzy osoczowym stężeniem omentyny i thrombospondyny-1 u kobiet z cukrzycą ciążową pomimo braku korelacji z insulinoopornością

Ginekologia Polska

Volumn 81, Issue 12, 2010, Pages 907-912

  Lewandowski, Krzysztof ^a,b   Nadel, Iwona ^a   Lewinski, Andrzej ^a   Bienkiewicz, Małgorzata ^a   Tan, B ^b   Randeva, Harpal S ^b   Cypryk, Katarzyna ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Gestational diabetes; Insulin resistance; Omentin; Thrombospondin 1

Indexed keywords

EID: 78651515677     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Kershaw E, Flier J. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004, 89, 2548-2556.
2. Spranger J, Kroke A, Möhlig M, [et al.]. Adiponectin and protection against type 2 diabetes mellitus. Lancet. 2003, 361, 226-228.
3. Harlev A, Wiznitzer A. New insights on glucose pathophysiology in gestational diabetes and insulin resistance. Curr Diab Rep. 2010, 10, 242-247.
4. Volpe L, Di Cianni G, Lencioni C, [et al.]. Gestational diabetes, infammation, and late vascular disease. J Endocrinol Invest. 2007, 30, 873-879.
5. Kuzmicki M, Telejko B, Szamatowicz J, [et al.]. High resistin and interleukin-6 levels are associated with gestational diabetes mellitus. Gynecol Endocrinol. 2009, 25, 258-263.
6. Szamatowicz J, Kuźmicki M, Telejko B, [et al.]. Serum visfatin concentration is elevated in pregnant women irrespectively of the presence of gestational diabetes. Ginekol Pol. 2009, 80, 14-18.
7. Tan B, Adya R, Farhatullah S, [et al.]. Omentin-1, a Novel Adipokine, is decreased in Insulin Resistant Women with the Polycystic Ovary Syndrome: ex vivo and in vivo Regulation of Omentin-1 by Insulin and Glucose. Diabetes. 2008, 57, 801-808.
8. Tan B, Syed F, Lewandowski K, [et al.]. Circadian oscillation of circulating prothrombotic thrombospondin-1: ex vivo and in vivo regulation by insulin. J Thromb Haemost. 2008, 6, 1827-1830.
9. Varma V, Yao-Borengasser A, Bodles A, [et al.]. Thrombospondin-1 is an adipokine associated with obesity, adipose inflammation, and insulin resistance. Diabetes. 2008, 57, 432-439.
10. Weiss P, Haeusler M, Kainer F, [et al.]. Toward universal criteria for gestational diabetes: relationships between seventy-five and one hundred gram glucose loads and between capillary and venous glucose concentrations. Am J Obstet Gynecol. 1998, 178, 830-835.
11. WHO consultation: Definition, Diagnosis, and Classification of Diabetes Mellitus and Its Complications Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: WHO/NCD/NCS/99.2, World Health Org. 1999.
12. Matthews D, Hosker J, Rudenski A, [et al.]. Homeostasis model assessment: insulin resistance and cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985, 28, 412-419.
13. Matsuda M, DeFronzo R. Insulin sensitivity indices obtained from oral glucose tolerance testing: Comparison with the englycemic insulin clamp. Diabetes Care. 1999, 22, 1462-1470.
14. Schäffler A, Neumeier M, Herfarth H, [et al.]. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta. 2005, 1732, 96-102.
15. de Souza Batista C, Yang R, Lee M, [et al.]. Omentin plasma levels and gene expression are decreased in obesity. Diabetes. 2007, 56, 1655-1661.
16. Moreno-Navarrete J, Catalán V, Ortega F, [et al.]. Circulating omentin concentration increases after weight loss. Nutr Metab (Lond). 2010, 7, 27.
17. Mertens I, Verrijken A, Michiels J, [et al.]. Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. Int J Obes (Lond). 2006, 30, 1308-1314.
18. Pan H, Guo L, Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract. 2010, 88, 29-33.
19. Telejko B, Kuzmicki M, Wawrusiewicz-Kurylonek N, [et al.]. Plasma apelin levels and apelin/APJ mRNA expression in patients with gestational diabetes mellitus. Diabetes Res Clin Pract. 2010, 87, 176-183.
20. Lewandowski K, Stojanovic N, Bienkiewicz M, [et al.]. Elevated concentrations of retinol-binding protein-4 (RBP-4) in gestational diabetes mellitus: negative correlation with soluble vascular cell adhesion molecule-1 (sVCAM-1). Gynecol Endocrinol. 2008, 24, 300-305.
21. Tan B, Adya R, Chen J, [et al.]. Metformin decreases angiogenesis via NF-kB and Erk1/2/Erk5 pathways by increasing the antiangiogenic thrombospondin-1. Cardiovascular Research. 2009, 83, 566-574.
22. Wurm S, Neumeier M, Weigert J, [et al.]. Plasma levels of leptin, omentin, collagenous repeat-containing sequence of 26-kDa protein (CORS-26) and adiponectin before and after oral glucose uptake in slim adults. Cardiovasc Diabetol. 2007, 6, 7.
23. Yang R, Lee M, Hu H, [et al.]. Identification of omentin as a novels depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab. 2006, 290, E1253-E1261.
24. Yamawaki H, Tsubaki N, Mukohda M, [et al.]. Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochem Biophys Res Commun. 2010, 393, 668-672.
25. Murphy-Ullrich J, Poczatek M. Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev. 2000, 11, 59-69.
26. Esemuede N, Lee T, Pierre-Paul D, [et al.]. The role of thrombospondin-1 in human disease. J Surg Res. 2004, 122, 135-142.